Phapros Distributes 40 Percent Dividend Of Net Profit Or Around IDR 19.4 Billion

Photo: Doc. Phapros

JAKARTA - PT Phapros Tbk, one of the national pharmaceutical issuers and also a subsidiary of PT Kimia Farma Tbk, held a General Meeting of Shareholders (GMS) for the 2020 Fiscal Year in Jakarta. In this year's GMS, management explained the company's performance achievements throughout 2020.

Despite being affected by the COVID-19 pandemic, in 2020 Phapros managed to pocket sales of more than IDR 980 billion. The Managing Director of Phapros, Hadi Kardoko said that the increase in sales of Phapros in 2020 was dominated by the generic oat segment with the logo (OGB), which increased by 13 percent from the previous year amounting to IDR 738 billion.

"The year 2020 was a year full of challenges for us. Although the company's performance last year experienced a correction, in the first quarter of 2021, we managed to reverse the situation", said Hadi.

In the 2020 GMS, it was agreed to distribute cash dividends of 40 percent of net income or approximately IDR 19.4 billion to shareholders.

In addition, this year's GMS also decided to change the management of the Company, so that the composition is as follows:

Board of Commissioners

President Commissioner: Maxi Rein Rondonuwu

Commissioner: Masrizal Achmad Syarief

Independent Commissioner: Zainal Abidin

Independent Commissioner: Chrisma Aryani Albandjar

Directors

President Director: Hadi Kardoko

Director of Finance and Risk Management: David ES Sidjabat

Production Director: Syamsul Huda

Marketing Director: Tri Andayani

To continue to improve their performance in the midst of today's challenging conditions, Hadi Kardoko said that, the board of directors of PT Phapros Tbk had compiled various strategic plans.

"We will carry out strategic business development consisting of organic business development, launching of new products this year and the next two years, as well as increasing utility through harmonization in the Phapros Group", he said.

Hadi said that in 2021 and 2022, Phapros has a target of at least 10 new product launches.

"The new products to be launched come from several therapeutic classes, including antibiotics, antidiabetic, anti-cholesterol, which are first-line therapy products, thus adding to the completeness of PT Phapros Tbk products", he explained.

He also added that until 2023, Phapros' new product portfolio will consist of 63 percent branded and 37 percent generic. The management of PT Phapros Tbk believes that the performance until the end of this year will continue to increase sharply so that the double-digit growth target, both revenue and net profit, will be achieved.

For information, in the first quarter of 2021, Phapros recorded performance with a net profit position of IDR 7.18 billion, an increase of 254 percent.

"The EBITDA also increased by IDR 46.82 billion or 465 percent (yoy) after implementing a number of adaptive and innovative strategies in terms of products, finance, and marketing during the pandemic", said Hadi.